Resource Summary Report

Generated by RRID on Aug 10, 2026

CD276-PE

RRID:AB_10831020
Type: Antibody

Proper Citation

Miltenyi Biotec Cat# 130-095-525, RRID:AB_10831020

Antibody Information

URL: http://antibodyregistry.org/AB_10831020

Proper Citation: Miltenyi Biotec Cat# 130-095-525, RRID:AB_10831020

Target Antigen: CD276

Host Organism: mouse

Clonality: monoclonal

Comments: Discontinued: 3-2019; Target Distribution B cells, dendritic cells, epithelial cells, heart, liver, monocytes, NK cells, pancreas, placenta, small intestine, T cells; target type CD markers; tested applications MACS Flow Cytometry; quantity:
Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-120-712. (RRID:AB_2784099).

Antibody Name: CD276-PE

Description: This monoclonal targets CD276

Target Organism: human

Clone ID: FM276

Antibody ID: AB_10831020

Vendor: Miltenyi Biotec

Catalog Number: 130-095-525

Record Creation Time: 20250820T042744+0000

Record Last Update: 20250820T190216+0000

Ratings and Alerts

No rating or validation information has been found for CD276-PE.

Warning: Discontinued: 2021
Discontinued: 3-2019; Target Distribution B cells, dendritic cells, epithelial cells, heart, liver, monocytes, NK cells, pancreas, placenta, small intestine, T cells; target type CD markers; tested applications MACS Flow Cytometry; quantity:
Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-120-712. (RRID:AB_2784099).

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 1 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Yamato M, et al. (2022) DS-7300a, a DNA Topoisomerase I Inhibitor, DXd-Based Antibody-Drug Conjugate Targeting B7-H3, Exerts Potent Antitumor Activities in Preclinical Models. Molecular cancer therapeutics, 21(4), 635.